A global contract developer says it is among the first to offer a standardized approach to manufacturing adeno-associated viruses (AAVs) and lentiviruses (LVVs) for advanced therapies. AGC Biologics ...
Based on Ajinomoto Group’s collaborative development with Forge Biologics, now available worldwide Incheon, Korea — December 2025 — Ajinomoto CELLiST Korea, a subsidiary of the Ajinomoto Group ...
PHILADELPHIA--(BUSINESS WIRE)--VintaBio, a biotech manufacturing technology company specializing in high-yield, high-purity viral vector production for reliable gene therapy access, will present ...
Key market opportunities include the rising prevalence of chronic diseases and increased regulatory approvals driving demand ...
Advances company’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing Mirus Bio’s leading GMP transfection reagents complement company’s upstream ...
Viral vector-based cell therapy uses modified viruses to deliver a healthy gene into a cell to treat a disease. The virus’ shell delivers the gene and the vectors, with the genetic information they ...
Viral vectors are a key component of many advanced gene therapies and vaccines, but reliable, large-scale manufacturing remains a significant challenge. Continued innovation in vector design, cell ...
Viral vector manufacturing continues to face challenges in delivering consistent quality and achieving high productivity at scale. This webinar will highlight how CDMO innovation drives improvements ...
The SK pharmteco group is now offering a standardized viral vector and plasmid manufacturing process to a global audience. The global approach can help customers move to batches for clinical trials in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results